2. Search Result
Search Result
Results for "

loxl2+inhibitor

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101771A
    (2-Chloropyridin-4-yl)methanamine hydrochloride
    Maximum Cited Publications
    9 Publications Verification

    		 Monoamine Oxidase Cardiovascular Disease Inflammation/Immunology
    (2-Chloropyridin-4-yl)methanamine hydrochloride is a selective LOXL2 inhibitor with an IC50 of 126 nM.
    (2-Chloropyridin-4-yl)methanamine hydrochloride
  • HY-107422
    Lenumlostat
    3 Publications Verification

    PAT-1251; GB2064

    		 Monoamine Oxidase Inflammation/Immunology
    PAT-1251 is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with IC50s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC50s, 0.10, 0.12, and 0.16 μM, respectively); PAT-1251 is used in the research of fibrotic diseases .
    Lenumlostat
  • HY-N0554
    Escin IA
    1 Publications Verification

    		 HIV Protease Monoamine Oxidase Infection Inflammation/Immunology Cancer
    Escin IA is an oral LOXL2 inhibitor and EMT inhibitor, with selectivity for LOXL2-expressing cells. Escin IA suppresses invasion, migration, and metastasis of breast cancer cells, and acts as the primary anti-TNBC metastasis constituent of Aesculus chinensis Bunge fruit saponin fraction. Escin IA can be used for the research of triple-negative breast cancer, acute inflammation, and ethanol-induced gastric mucosal lesions [2] .
    Escin IA
  • HY-170573A
    LOXL2-IN-1 tosylate

    		Monoamine Oxidase Cancer
    LOX-IN-5 tosylate (compound 22) is a selective and orally active lysyl oxidase-like 2 (LOXL2) inhibitor with an IC50 of <300 nM. LOX-IN-5 tosylate possess anti-fibrosis properties .
    LOXL2-IN-1 tosylate
  • HY-170573
    LOXL2-IN-1

    		Monoamine Oxidase Cancer
    LOX-IN-5 (compound 22) is a selective and orally active lysyl oxidase-like 2 (LOXL2) inhibitor with an IC50 of <300 nM. LOX-IN-5 possess anti-fibrosis properties .
    LOXL2-IN-1
  • HY-107422A
    Lenumlostat hydrochloride

    PAT-1251 hydrochloride; GB2064 hydrochloride

    		 Monoamine Oxidase Inflammation/Immunology
    PAT-1251 Hydrochloride is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with IC50s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC50s, 0.10, 0.12, and 0.16 μM, respectively). PAT-1251 Hydrochloride is used in the research of fibrotic diseases.
    Lenumlostat hydrochloride
  • HY-101771AR
    (2-Chloropyridin-4-yl)methanamine hydrochloride (Standard)

    		Reference Standards Monoamine Oxidase Cardiovascular Disease Inflammation/Immunology
    (2-Chloropyridin-4-yl)methanamine hydrochloride (Standard) is the analytical standard of (2-Chloropyridin-4-yl)methanamine hydrochloride (HY-101771A). This product is intended for research and analytical applications. (2-Chloropyridin-4-yl)methanamine hydrochloride is a selective LOXL2 inhibitor with an IC50 of 126 nM.
    (2-Chloropyridin-4-yl)methanamine hydrochloride (Standard)
  • HY-107422R
    Lenumlostat (Standard)

    PAT-1251 (Standard); GB2064 (Standard)

    		 Reference Standards Monoamine Oxidase Inflammation/Immunology
    Lenumlostat (Standard) is the analytical standard of Lenumlostat (HY-107422). This product is intended for research and analytical applications. PAT-1251 is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with IC50s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC50s, 0.10, 0.12, and 0.16 μM, respectively); PAT-1251 is used in the research of fibrotic diseases .
    Lenumlostat (Standard)
  • HY-183644
    LNO 9

    		Lysyl Oxidase Cardiovascular Disease
    LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
    LNO 9
  • HY-180581
    LOXL2/sGC modulator-1

    		Monoamine Oxidase Guanylate Cyclase Cardiovascular Disease
    LOXL2/sGC modulator-1 (Compound 11k) is a LOXL2 inhibitor (IC₅₀ = 0.13 μM) and an sGC activator. LOXL2/sGC modulator-1 shows good selectivity for LOX (IC₅₀ > 45.9 μM) and LOXL3 (IC₅₀ = 1.30 μM). LOXL2/sGC modulator-1 significantly increases intracellular cGMP levels in the presence of the gGC inhibitor ODQ (HY-101255). LOXL2/sGC modulator-1 significantly inhibits hypoxia-induced collagen deposition and cross-linking, while promoting vasodilation. LOXL2/sGC modulator-1 can be used for the study of pulmonary arterial hypertension .
    LOXL2/sGC modulator-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: